Cargando…
Bevacizumab versus PARP-inhibitors in women with newly diagnosed ovarian cancer: a network meta-analysis
BACKGROUND: In women with newly diagnosed ovarian cancer, bevacizumab and poly (ADP-ribose) polymerase inhibitors (PARPi) exhibit improved progression-free survival (PFS) when administered concurrent with chemotherapy and/or maintenance therapy, but no study has directly compared their effects. Ther...
Autores principales: | Suh, Young Ju, Lee, Banghyun, Kim, Kidong, Jeong, Yujin, Choi, Hwa Yeon, Hwang, Sung Ook, Kim, Yong Beom |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8969379/ https://www.ncbi.nlm.nih.gov/pubmed/35354431 http://dx.doi.org/10.1186/s12885-022-09455-x |
Ejemplares similares
-
Risk factors of progression to endometrial cancer in women with endometrial hyperplasia: A retrospective cohort study
por: Jeong, Jin Young, et al.
Publicado: (2020) -
Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis
por: Lee, Banghyun, et al.
Publicado: (2023) -
Postoperative Hormone Replacement Therapy and Survival in Women with Ovarian Cancer
por: Ji, Eunjeong, et al.
Publicado: (2022) -
Incidence and risk of venous thromboembolism according to primary treatment in women with ovarian cancer: A retrospective cohort study
por: Yuk, Jin-Sung, et al.
Publicado: (2021) -
Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer
por: Hettle, Robert, et al.
Publicado: (2021)